MarketScreener Strategies Vertex Pharmaceuticals Incorporated
Stocks
VRTX
US92532F1003
Pharmaceuticals
|
Market Closed -
Nasdaq
23:00:00 21/08/2026 +03
|
5-day change | 1st Jan Change | ||
| 548.05 USD | +1.44% |
|
+8.36% | +20.89% |
| 08-12 | Vertex Has Multiple Portfolio Catalysts With Favorable Risk-Reward, RBC Says | MT |
| 08-11 | Jefferies Adjusts Price Target on Vertex Pharmaceuticals to $633 From $610, Maintains Buy Rating | MT |
MarketScreener Strategies
Search
 | Vertex Pharmaceuticals Incorporated : Vertex and Crispr to market $2.2 million treatment for sickle cell disease | December 11, 2023 at 01:47 pm |
 | Vertex Pharmaceuticals Incorporated : Confirms growth trajectory | May 04, 2023 at 04:35 pm |
 | Vertex Pharmaceuticals : A very promising pipeline | January 11, 2023 at 01:20 pm |
No results match your criteria
- Stock Market
- Stocks
- VRTX Stock
- News Vertex Pharmaceuticals Incorporated
- MarketScreener Strategies
Select your edition
All financial news and data tailored to specific country editions
